The landscape of obesity treatment has changed dramatically over the past few years. What was once a field dominated by lifestyle counseling and bariatric surgery now includes a powerful pharmaceutical option: injectable weight loss medications. Drugs such as (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide) have captured global attention, with demand often outpacing supply. Social media feeds are filled with dramatic before-and-after photos, and celebrities have spoken openly about their use. In Hong Kong alone, prescriptions for GLP-1 receptor agonists have risen sharply, reflecting a broader trend across Asia and the West.
These medications are not merely cosmetic aids. They mimic hormones that regulate appetite and blood sugar, offering meaningful help to people living with obesity and related metabolic conditions. Clinical trials have shown weight losses of 15% or more of body weight—figures previously achievable only through surgery. For many, that translates into improved mobility, better cardiovascular markers, and a renewed sense of hope.
Yet enthusiasm must be tempered by caution. Injections are not a magic bullet. They carry side effects, require significant financial commitment, and demand ongoing medical supervision. Some users regain weight after stopping, and rare but serious complications exist. The decision to start—or continue—should never be made lightly or solely based on online testimonials. This article unpacks both the benefits and the risks so you can approach the choice with clarity and realism. Whether you are considering wegovy or another injectable, a balanced perspective is your most valuable asset.
The most obvious allure is results. In the STEP clinical program, participants taking Wegovy (semaglutide 2.4 mg) lost an average of 14.9% of their initial body weight over 68 weeks, compared with just 2.4% in the placebo group. A substantial proportion—over one-third—lost more than 20%. These are not trivial numbers. For someone weighing 100 kg, that could mean shedding 15 to 20 kg. Unlike many short-term diets, the weight loss tends to be sustained as long as the medication continues. The mechanism is physiological, not merely willpower-based: the drug slows gastric emptying and acts on brain receptors to reduce hunger, making adherence to reduced-calorie eating far more achievable.
Weight loss injections do more than shrink waistlines. They improve key markers of cardiometabolic health. In trials, Wegovy reduced systolic blood pressure by roughly 5–7 mmHg, lowered LDL cholesterol, and decreased triglycerides. For people with type 2 diabetes, semaglutide improves glycemic control, often reducing HbA1c by 1.0–1.5 percentage points. In Hong Kong, where diabetes prevalence is around 10% among adults, such improvements could translate into fewer heart attacks, strokes, and kidney complications. The SELECT trial further showed a 20% reduction in major cardiovascular events among overweight or obese adults with existing heart disease who took semaglutide. These are hard outcomes, not just surrogate markers.
Many users describe a profound shift in their relationship with food. The constant mental chatter about meals, snacks, and portion sizes fades. One patient in Hong Kong reported that for the first time in years, she could walk past a bakery without stopping. This is not simply suppression; the medication modulates reward pathways in the brain, reducing the dopamine-driven urge to eat for pleasure rather than hunger. That can be liberating for people who have struggled with emotional eating or food addiction. It also makes it easier to choose nutritious foods, as the urgency of cravings diminishes.
Unlike daily pills that must be timed around meals, most injectables are administered once weekly. The pen device is relatively easy to use, with a short, fine needle. For those with busy schedules or medication fatigue, this simplicity improves adherence. In clinical practice, adherence rates for weekly GLP-1 injections are higher than for many oral anti-obesity medications. The convenience also reduces the risk of forgetting doses, which can lead to suboptimal results.
The downstream effects can be transformative. Weight loss of 10–15% often leads to reduced joint pain, better sleep (especially for those with obstructive sleep apnea), improved fertility, and greater mobility. Many users report increased confidence and social participation. From a public health perspective, sustained weight loss lowers the risk of obesity-related cancers, fatty liver disease, and severe COVID-19 outcomes. In Hong Kong, where obesity rates have climbed to nearly 30% among adults, these benefits could ease pressure on the healthcare system. For the individual, the gain is not just years of life but quality of those years.
Gastrointestinal symptoms are the most frequent complaints. Nausea tops the list, affecting up to 44% of users in trials. Vomiting, diarrhea, constipation, and heartburn are also common. These effects are usually mild to moderate and often subside after a few weeks as the body adjusts. However, they can be disruptive. Some people find that fatty or spicy foods worsen nausea, leading to dietary changes. In Hong Kong, where dim sum and rich sauces are staples, patients may need to modify their eating habits. Managing these symptoms involves eating smaller meals, staying hydrated, and sometimes using anti-nausea medications. Rarely, symptoms are severe enough to require dose reduction or discontinuation.
More concerning are the uncommon but serious complications. Pancreatitis (inflammation of the pancreas) has been reported, though the absolute risk remains low—roughly 1 in 500 to 1 in 1,000 users per year. Gallbladder problems, including gallstones and cholecystitis, occur more frequently with rapid weight loss, especially in the first few months. For certain medications like liraglutide and semaglutide, boxed warnings exist for thyroid C-cell tumors, based on rodent studies. Human data have not confirmed this risk, but anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome should avoid these drugs. In Hong Kong, the Department of Health has issued safety alerts reminding prescribers to monitor for these rare events. The key is not to panic but to recognize warning signs—severe abdominal pain, persistent vomiting, or a neck lump—and seek medical attention promptly.
Local reactions at the injection site—redness, itching, swelling, or a small bruise—are common but usually minor. Rotating injection sites (abdomen, thigh, upper arm) helps prevent lipohypertrophy (fatty lumps). Using a new needle each time and allowing the pen to reach room temperature before injecting can reduce discomfort. Some users experience a mild burning sensation; this typically lasts only seconds. If reactions persist or worsen, a healthcare provider can assess for infection or allergy. Proper storage of the pen (refrigerated before first use, then room temperature or refrigerated) is also important to maintain efficacy and sterility.
Rapid weight loss is not always fat loss. Studies show that up to 20–40% of the weight lost on GLP-1 medications can be lean muscle mass. This is concerning because muscle is metabolically active, supports strength and balance, and helps regulate blood sugar. Without adequate protein (aim for 1.2–1.6 g per kg of ideal body weight) and resistance training at least two to three times per week, users may end up weaker, with a lower metabolic rate. In Hong Kong, where many older adults already have low muscle mass (sarcopenia), this risk is especially relevant. Measuring body composition with DEXA or bioelectrical impedance can help track muscle versus fat loss. The message is clear: injections alone are not enough; they should be paired with a muscle-preserving lifestyle.
Obesity is a chronic condition. When Wegovy or similar drugs are stopped, appetite returns, and weight regain is common. In the STEP 1 extension trial, participants regained about two-thirds of their lost weight within one year of stopping the medication. This is not a failure of willpower; it reflects the biological drive to defend a higher body weight. For many, discontinuing the injection means returning to the starting point. This raises important questions: Is the medication intended for lifelong use? Can lower maintenance doses or intermittent therapy help? Current evidence suggests that ongoing treatment is often necessary to sustain benefits. Patients should discuss an exit strategy—or a plan for long-term maintenance—before starting, not after.
Weight loss injections are expensive. In Hong Kong, a monthly supply of Wegovy can cost between HK$3,000 and HK$5,000, depending on the pharmacy and dose. Saxenda is similarly priced, while Mounjaro may be higher. Few insurance plans cover these medications for obesity alone; coverage is more likely if the patient has type 2 diabetes or a history of cardiovascular disease. Even then, prior authorization is often required, with documentation of BMI, comorbidities, and failed lifestyle interventions. Many patients pay out of pocket. In the public sector, availability is limited, and waiting lists can be long. This creates an equity problem: those who need the medication most may be least able to afford it.
Because weight regain is likely upon discontinuation, the financial commitment is not short-term. A year of treatment could cost HK$36,000–HK$60,000. Over five years, that approaches the cost of a small car. Patients must weigh this against other expenses and savings goals. Some employers offer wellness programs that partially reimburse, but these are rare in Hong Kong. Generic versions of semaglutide are not yet available in most markets, though this may change after patent expirations. For now, budgeting for the long haul is essential. Stopping and restarting due to financial constraints can lead to yo-yo weight loss, which carries its own health risks.
No one should start an injectable weight loss medication without a thorough evaluation by a physician, ideally one with expertise in obesity medicine or endocrinology. The assessment should include a review of medical history, current medications, family history of thyroid cancer or pancreatitis, and a physical exam. Baseline blood tests—liver enzymes, kidney function, pancreatic enzymes, and thyroid profile—are prudent. A healthcare provider can also screen for eating disorders, as these drugs may exacerbate restrictive behaviors or be misused. In Hong Kong, registered dietitians and clinical psychologists often collaborate with doctors to provide holistic care. Follow-up visits every 4–8 weeks allow for dose titration, side effect management, and monitoring of muscle mass and nutritional status. The goal is not just weight loss but health improvement.
Beyond medical eligibility, personal circumstances matter. Do you have the time and resources for regular follow-ups? Can you afford the medication indefinitely? Are you willing to commit to protein-rich meals and strength training? Do you have a support system for emotional challenges? Some people thrive on the structure; others find the side effects or cost too burdensome. There is no shame in deciding that injections are not for you. Alternatives include intensive lifestyle programs, other medications (e.g., phentermine-topiramate, naltrexone-bupropion), or bariatric surgery. A candid conversation with your doctor can help align the treatment with your values and life situation.
Weight loss injections like Wegovy represent a genuine breakthrough in obesity medicine. They offer substantial, sustained weight loss, metabolic improvements, and better quality of life for many. But they are not risk-free. Gastrointestinal side effects, rare serious complications, muscle loss, weight regain, and high costs demand careful thought. The best outcomes occur when these medications are part of a comprehensive program that includes nutrition, exercise, and psychological support. If you are considering injections, arm yourself with evidence, consult a trusted healthcare professional, and go in with your eyes open. A powerful tool can change lives—but only when used wisely, safely, and with realistic expectations.